ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 80 • 2014 ACR/ARHP Annual Meeting

    Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry

    Michael Kruse Meyer1, Marlene Andersen2, Grethe N. Andersen1 and Allan Stensballe3, 1Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, 2Department of Rheumatology, Aalborg University, Hjørring, Denmark, 3Health Science and Technology, Aalborg University, Aalborg, Denmark

    Background/Purpose: In this study we are analyzing leukocyte subtype responses from patients with rheumatoid arthritis (RA) to IL6 inhibition. A large contribution to RA immunopathogenesis…
  • Abstract Number: 2506 • 2014 ACR/ARHP Annual Meeting

    Decrease in the Number of Peripheral Leukocytes and Neutrophils and Increase of the Percentage of Eosinophils at 4 Week Predict the DAS28-ESR Remission at 24 Weeks after Administration of Tocilizumab

    Tamao Nakashita1, Shinji Motojima2 and Akira Jibatake3, 1[email protected], Kameda Medical Center, Kamogawa-city, Japan, 2[email protected], Kameda Medical Center, Kamogawa City, Japan, 3Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan

    Background/Purpose : Tocilizumab (TCZ) is a monoclonal anti-IL-6 receptor antibody, and is very effective in controlling RA activity.  However we had noticed that the change…
  • Abstract Number: 2827 • 2013 ACR/ARHP Annual Meeting

    Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients

    Dimitrios A. Pappas1, Ani John2, Jeffrey R. Curtis3, George W. Reed4, Jeffrey D. Greenberg5, Ashwini Shewade2, Daniel H. Solomon6, Joel M. Kremer7 and Tanya Sommers4, 1Columbia University, New York, NY, 2Genentech Inc., South San Francisco, CA, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4CORRONA, Inc., Southborough, MA, 5Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, 6Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 7Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose: The risk for cardiovascular disease (CVD) is increased in patients (pts) with RA. The interplay between traditional CV risk factors and inflammatory burden may…
  • Abstract Number: 2387 • 2013 ACR/ARHP Annual Meeting

    Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient

    Chisa Okura1, Yukio Yonemoto2, Koichi Okamura1, Tetsuya Kaneko3, Tsutomu Kobayashi1 and Kenji Takagishi1, 1Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 2Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, 3Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan

    Background/Purpose: The C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum…
  • Abstract Number: 2389 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab Survives Introducing The Hemadialysis Longer Than Oral Medicine In AA Amyloidosis Patients With Rheumatoid Arthritis Of Renal Insufficiency

    Osamu Saiki1, Hiroshi Uda1, Ayumi Matsumoto2, Aya Mizumoto3, Tamaki Harada3 and Toshirou Takama3, 1Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, 2Higashiosaka City General Hospital, Higashiosaka, Japan, 3Nephrology, Higashiosaka City General Hospital, Higashiosaka, Japan

    Background/Purpose: In AA amyloidosis patients with RA taking oral medicines such as methotrexate and prednisolone, it is generally accepted that the renal function deteriorates gradually…
  • Abstract Number: 2390 • 2013 ACR/ARHP Annual Meeting

    Low Dose Of Tocilizumab Can Be Effective In RA Patients Who Achieve Remission.

    Cecilia Prieto- Candau1, Virginia Moreira- Navarrete2, Carmen Vargas-Lebrón2, Juan M Prieto-Martinez2, Dolores Ruiz-Montesinos2, Javier Toyos-Saenz de Miera2 and Federico Navarro-Sarabia3, 1Rheumatology, Hospital Virgen Macarena, SEVILLE, Spain, 2Rheumatology, Hospital Virgen Macarena, Seville, Spain, 3Rheumatology, Hospital Virgen Macarena, Serv. de Reumatología, Sevilla, Spain

    Background/Purpose: Tocilizumab (TCZ), an anti-IL-6-receptor antibody, is used for the treatment of moderate to severe rheumatoid arthritis (RA) in adults with inadequate response or intolerance…
  • Abstract Number: 2368 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab Efficiently Halts Radiographic Progression In Patients With Rheumatoid Arthritis and Swollen Joint Counts Within a Year Predict Long-Term Radiographic Outcomes: Three Year Results From Michinoku Tocilizumab Study Group

    Ryu Watanabe1, Hiroshi Okuno2, Tomonori Ishii1, Yasuhiko Hirabayashi3 and Hideo Harigae1, 1Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 2Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, 3Rheumatology, Hikarigaoka Spellman Hospital, Sendai, Japan

    Background/Purpose: One of the important therapeutic goals in patients with rheumatoid arthritis (RA) is to halt radiographic progression. Tocilizumab (TCZ), an IL-6 receptor antibody, has…
  • Abstract Number: 2343 • 2013 ACR/ARHP Annual Meeting

    Assessment Of Subclinical Atherosclerosis (Flow Mediated Dilatation and arterial stiffness) After 24 Weeks Of a Tocilizumab Therapy In 22 Patients With Rheumatoid Arthritis

    Martin Soubrier1, Thomas Frayssac2, Bruno Pereira3, Marion Couderc Sr.4, Coline Daron2, Jean Jacques Dubost5, Sandrine Malochet-Guinamand4, Anne Tournadre4 and Sylvain Mathieu4, 1Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, 2CHU CLERMONT-FERRAND, Clermont-ferrand, France, 3Clinical research department, Clermont-Ferrand, France, 4Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, 5Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France

    Background/Purpose:  Increased incidence of cardiovascular diseases and sub-clinical atherosclerosis have been observed in rheumatoid arthritis (RA). Inflammation and  traditional risk factors could be involved in…
  • Abstract Number: 2327 • 2013 ACR/ARHP Annual Meeting

    Dose Reduction Of Tocilizumab In Rheumatoid Arthritis Patients With Low Disease Activity Is Feasible

    Noortje van Herwaarden1, Susan Herfkens-Hol1, Aatke van der Maas1, Bart J.F. van Den Bemt2, Ronald F. van Vollenhoven3, Johannes W.J. Bijlsma4 and Alfons A. den Broeder1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, 3Karolinska Institute, Stockholm, Sweden, 4Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Tocilizumab, at a registered dose of 8mg/kg, has proven to be effective in the treatment of rheumatoid arthritis. Clinical trial data show that a…
  • Abstract Number: 2263 • 2013 ACR/ARHP Annual Meeting

    ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis

    Kensei Tsuzaka, Masako Takao and Jiro Nishida, Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan

    a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of tocilizumab (TCZ) for…
  • Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting

    Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX

    Toshihisa Kojima1, Nobunori Takahashi2, Koji Funahashi3, Shuji Asai1, Masahiro Hanabayashi1, Shinya Hirabara4, Nobuyuki Asai5 and Naoki Ishiguro2, 1Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, 2Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 4Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 5Nagoya Univeristy Hospital, Nagoya, Japan

    Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…
  • Abstract Number: 1437 • 2013 ACR/ARHP Annual Meeting

    Clinical and Radiographic Outcomes At Two Years and The Effect Of Tocilizumab Discontinuation Following Sustained Remission In The Second Year Of The ACT-RAY Study

    Thomas W.J. Huizinga1, Philip G. Conaghan2, Emilio Martin-Mola3, Georg Schett4, Howard Amital5, Ricardo M. Xavier6, Orrin Troum7, Maher Aassi8, Corrado Bernasconi9 and Maxime Dougados10, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 4Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B',, Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Tel-hashomer, Israel, 6Rheumatology Division, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 7University of Southern California School of Medicine, Santa Monica, CA, 8F. Hoffmann-La Roche, Basel, Switzerland, 9Consultant, Basel, Switzerland, 10Cochin Hospital, Paris, France

    Background/Purpose: 24- and 52- week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO])…
  • Abstract Number: 1440 • 2013 ACR/ARHP Annual Meeting

    Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease-Modifying Antirheumatic Drugs

    Sang Jin Lee1,2, Kyung Rok Kim3, Sang Hyun Joo3, Jae Myung Lee3, In Ah Choi3, Joo Youn Lee2, Hyun Jung Yoo2, Eun Young Lee4, Eun Bong Lee1, Won Park5, Sung Hwan Park6, Seung-Cheol Shim7, Dae-Hyun Yoo8, Han Joo Baek9, Hyun Ah Kim10, Soo Kon Lee11, Yun Jong Lee1, Young Eun Park12, Hoon-Suk Cha13 and Yeong Wook Song2,3, 1Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, 2Department of molecular medicine and biophamaceutical sciences,Seoul National University, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 4Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Rheumatology, The Catholic University, Seoul, South Korea, 7Medicine, Rheumatology, Eulji University, Daejeon, South Korea, 8Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 9Rheumatology, Rheumatology, Gachon University, Incheon, South Korea, 10Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, 11Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 12Rheumatology, Rheumatology, Pusan Nationl University, Pusan, South Korea, 13Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Background/Purpose: The objective of this study was to investigate the effects of tocilizumab on serum cytokines in rheumatoid arthritis (RA) patients with an inadequate response…
  • Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting

    Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort

    Eiichi Tanaka1, Eisuke Inoue2, Yoko Shimizu3, Akiko Kobayashi2, Naoki Sugimoto2, Daisuke Hoshi2, Kumi Shidara2, Eri Sato3, Yohei Seto2, Ayako Nakajima4, Shigeki Momohara2, Atsuo Taniguchi2 and Hisashi Yamanaka3, 1Tokyo Women's Medical University, Tokyo, Japan, 2Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 4Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…
  • Abstract Number: 448 • 2013 ACR/ARHP Annual Meeting

    Effectiveness Of Tocilizumab In Monotherapy and In Combination With Different Synthetic Dmards:  A Registry-Based Comparison Study

    Cem Gabay1, Myriam Riek2, Merete Lund Hetland3, Ulrik Tarp4, K. Pavelka5, Matija Tomsic6, Helena Canhao7, Katerina Chatzidionysiou8, R.F. van Vollenhoven9, Galina Lukina10, E. Nasonov11, Dan C. Nordström12, Elisabeth Lie13, Ioan Ancuta14, Estibaliz Loza Santamaria15, Piet Van Riel16 and Tore K. Kvien13, 1Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 2SCQM Registry, Zurich, Switzerland, 3DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, 4Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 5Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 6Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, 7Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, 8Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, 9Karolinska Institute, Stockholm, Sweden, 10ARBITER, Institute of Rheumatology, Moscow, Russia, 11Institute of Rheumatology, Moscow, Russia, 12ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 13Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 14“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, 15Instituto de salud Musculoesqueletica, Madrid, Spain, 16Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Tocilizumab (TCZ) is efficacious in monotherapy and in combination with methotrexate (MTX) or other DMARDs. However, longitudinal data from large registry populations are missing.…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology